Delaware | 001-37798 | 26-1622110 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit No. | Description | ||
99.1 | Press Release issued on August 11, 2017 |
SELECTA BIOSCIENCES, INC. | ||
Date: August 11, 2017 | By: | /s/ Werner Cautreels, Ph.D. |
Werner Cautreels, Ph.D. | ||
President and Chief Executive Officer |
Exhibit No. | Description | ||
99.1 | Press Release issued on August 11, 2017 |
• | Positive Data from Ongoing Phase 2 Study of SEL-212 Reported at Clinical Meetings in June 2017 |
• | Further Preclinical Data Confirm Immune Tolerance Platform’s Broad Potential |
• | Recent Financing Extends Cash Runway Into 2019 |
• | Company to Host Conference Call Today at 8:30 a.m. ET |
• | Presented SEL-212 Phase 2 Trial Data: In June 2017, Selecta presented clinical data from its ongoing open-label, multiple ascending dose Phase 2 trial of SEL-212 (SVP-Rapamycin in combination with pegsiticase) at the Annual European Congress of Rheumatology (EULAR 2017) and the Federation of Clinical Immunology Societies (FOCIS 2017). As of August 1, 2017, a total of 63 patients had been dosed in eight cohorts. No additional serious adverse events or new notable safety trends have been observed in the trial since the presentations in June. The company plans to report further data from this trial at a medical meeting in late 2017 and to initiate its Phase 3 program in 2018. |
• | Added a Clinical-Stage Oncology Asset: In May 2017, Selecta announced that it had licensed LMB-100, a clinical-stage, next-generation recombinant immunotoxin, from the Center for Cancer Research at the National Cancer Institute (NCI), part of National Institutes of Health. LMB-100 contains a potent toxin that is derived from Pseudomonas exotoxin A fused to an antibody fragment targeting mesothelin, which is overexpressed in virtually all mesotheliomas and pancreatic adenocarcinomas and a high percentage of other malignancies, including ovarian, lung and breast cancers. A precursor to LMB-100 was shown to induce marked tumor reduction and prolonged survival in mesothelioma patients in which an ADA response was inhibited by immunosuppressants; however, ADAs limited the number of cycles that could be administered in the vast majority of patients. Additionally, a July 2017 publication entitled “Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anti-Cancer Immunity” (Leshem Y et al) in Cancer Immunology Research described a preclinical study showing that a combination of LMB-100 and a checkpoint inhibitor induced complete mesothelioma regression in most mice. NCI is currently conducting two Phase 1 trials of LMB-100 in mesothelioma and pancreatic cancer, and Selecta and NCI are currently planning a Phase 1b clinical trial to evaluate multiple cycles of a combination treatment consisting of LMB-100 and SVP-Rapamycin. |
• | Announced New Gene Therapy Data: Additional preclinical data regarding non-immunogenic gene therapies were presented at the American Society of Gene & Cell Therapy (ASGCT) 2017 Annual Meeting in Washington, D.C. in May 2017. Selecta’s collaborators at the National Human Genome Research Institute and Massachusetts Eye and Ear presented preclinical proof-of-concept data showing the efficacy of the company’s methymalonic acidemia (MMA) gene therapy candidate and SVP-Rapamycin’s ability to mitigate immune responses to an Anc80 capsid. A team led by Federico Mingozzi, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, also presented preclinical data in mice and non-human primates indicating that co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses and allowed for vector re-administration and gene therapy dose titration. |
• | Published Preclinical Data in Pompe Disease: Molecular Genetics and Metabolism Reports published a paper in July 2017 from collaborators at Duke University led by Dr. Priya Kishnani entitled “A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.” These investigators utilized a mouse model of Pompe disease to show that the co-administration of SVP-Rapamycin with the enzyme replacement therapy alglucosidase alfa (marketed as Myozyme® and Lumizyme®) inhibited the formation of ADAs, reduced glycogen storage, and improved weight and motor skills compared to co-administration of the enzyme with the immunosuppressive methotrexate. |
• | Added a New Board Member: At Selecta’s 2017 Annual Meeting of Stockholders in June 2017, Patrick J. Zenner was elected to the company’s Board of Directors. Mr. Zenner previously served as President and Chief Executive Officer of Hoffmann-La Roche Inc., North America, the prescription drug unit of Roche. |
• | Raised $50 Million in Financing: Selecta completed a private placement with new and existing investors during the second quarter that resulted in gross proceeds to the company of $50 million, before deducting placement agent and other offering expenses. |
• | Revenue: For the second quarter of 2017, the company’s total revenue was less than $0.1 million, which compares with $2.0 million for the second quarter of 2016. The decline is primarily the result of reduced revenue recognized from the company’s nicotine vaccine candidate grant award from the National Institute on Drug Abuse, which is now winding down, as well as the previously announced termination of its collaboration with Sanofi. |
• | Research and Development Expenses: Research and development expenses for the second quarter of 2017 were $11.0 million, which compares with $6.0 million for the second quarter of 2016. The increase is primarily the result of clinical costs related to the company’s Phase 2 program for SEL-212, incremental headcount, and consulting, licensing, supplies and testing activities related to the company’s other pipeline programs. |
• | General and Administrative Expenses: General and administrative expenses for the second quarter of 2017 were $4.9 million, which compares with $2.4 million for the second quarter of 2016. The increase is primarily the result of greater expenses related to patents as well as general expenses and incremental salaries from increased headcount to support a clinical-stage public company. |
• | Net Loss: For the second quarter of 2017, Selecta reported a net loss attributable to common stockholders of $(16.0) million, or $(0.85) per share, compared to a net loss of $(9.1) million, or $(2.75) per share, for the same period in 2016. The decrease in net loss per share in the most recent quarter is primarily the result of shares of common stock that were issued in the company’s June 2016 initial public offering (IPO) and conversion of Selecta’s redeemable preferred stock into common stock in connection with the IPO, partially offset by an increase in net loss for the period. |
• | Cash Position: Selecta had $113.0 million in cash, cash equivalents, short-term deposits, investments and restricted cash as of June 30, 2017, which compares with a balance of $68.9 million at March 31, 2017. The increase is primarily the result of net proceeds from the company’s aforementioned private placement as well as cash payments associated with the company’s license and stock purchase agreements with Spark Therapeutics. Selecta expects that its cash, cash equivalents, short-term deposits, investments and restricted cash will be sufficient to fund the company’s operating expenses and capital expenditure requirements into 2019. |
June 30, 2017 | December 31, 2016 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 82,630 | $ | 58,656 | ||||
Short-term deposits and investments | 30,025 | 25,485 | ||||||
Restricted cash | 74 | 78 | ||||||
Accounts receivable | 1 | 215 | ||||||
Prepaid expenses and other current assets | 1,848 | 2,382 | ||||||
Total current assets | 114,578 | 86,816 | ||||||
Property and equipment, net | 2,131 | 2,047 | ||||||
Restricted cash and other deposits | 316 | 316 | ||||||
Other assets | — | 122 | ||||||
Total assets | $ | 117,025 | $ | 89,301 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 4,280 | $ | 3,882 | ||||
Accrued expenses | 8,595 | 3,921 | ||||||
Loans payable, current portion | 4,612 | 4,067 | ||||||
Deferred revenue, current portion | 2,566 | 1,836 | ||||||
Total current liabilities | 20,053 | 13,706 | ||||||
Non‑current liabilities: | ||||||||
Deferred rent and lease incentive | 189 | 222 | ||||||
Loans payable, net of current portion | 5,732 | 7,977 | ||||||
Deferred revenue, net of current portion | 11,619 | 12,439 | ||||||
Other long‑term liabilities | 1,250 | — | ||||||
Total liabilities | 38,843 | 34,344 | ||||||
Stockholders’ equity: | ||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively. | — | — | ||||||
Common stock, $0.0001 par value; 200,000,000 shares authorized; 22,056,147 and 18,438,742 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively. | 1 | 1 | ||||||
Additional paid-in capital | 265,297 | 211,125 | ||||||
Receivable from stock option exercises | (26 | ) | (75 | ) | ||||
Accumulated deficit | (182,677 | ) | (151,576 | ) | ||||
Accumulated other comprehensive loss | (4,413 | ) | (4,518 | ) | ||||
Total stockholders’ equity | 78,182 | 54,957 | ||||||
Total liabilities and stockholders’ equity | $ | 117,025 | $ | 89,301 |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Grant and collaboration revenue | $ | 26 | $ | 2,017 | $ | 163 | $ | 4,105 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 10,994 | 6,000 | 22,038 | 12,648 | ||||||||||||
General and administrative | 4,903 | 2,418 | 8,778 | 4,799 | ||||||||||||
Total operating expenses | 15,897 | 8,418 | 30,816 | 17,447 | ||||||||||||
Loss from operations | (15,871 | ) | (6,401 | ) | (30,653 | ) | (13,342 | ) | ||||||||
Investment income | 101 | 10 | 214 | 23 | ||||||||||||
Foreign currency transaction gain (loss), net | 82 | (158 | ) | (83 | ) | (378 | ) | |||||||||
Interest expense | (279 | ) | (310 | ) | (579 | ) | (620 | ) | ||||||||
Other expense, net | — | (64 | ) | — | (82 | ) | ||||||||||
Net loss | (15,967 | ) | (6,923 | ) | (31,101 | ) | (14,399 | ) | ||||||||
Other comprehensive loss: | ||||||||||||||||
Foreign currency translation adjustment | (43 | ) | 170 | 80 | 401 | |||||||||||
Unrealized gain (loss) on securities | 10 | — | 25 | — | ||||||||||||
Comprehensive loss | $ | (16,000 | ) | $ | (6,753 | ) | $ | (30,996 | ) | $ | (13,998 | ) | ||||
Net loss | (15,967 | ) | (6,923 | ) | (31,101 | ) | (14,399 | ) | ||||||||
Accretion of redeemable convertible preferred stock | — | (2,210 | ) | — | (4,566 | ) | ||||||||||
Net loss attributable to common stockholders | $ | (15,967 | ) | $ | (9,133 | ) | $ | (31,101 | ) | $ | (18,965 | ) | ||||
Net loss per share attributable to common stockholders | ||||||||||||||||
Basic and diluted | $ | (0.85 | ) | $ | (2.75 | ) | $ | (1.67 | ) | $ | (6.90 | ) | ||||
Weighted average common shares outstanding | ||||||||||||||||
Basic and diluted | 18,814,570 | 3,322,546 | 18,645,339 | 2,749,105 |